抗血管生成小分子酪氨酸激酶抑制剂在软组织肉瘤中的应用现状及展望  

Current status and prospects of anti-angiogenic small-molecule tyrosine kinase inhibitors in the therapy of soft tissue sarcoma

作　　者：范丽[1] 叶挺 陈静[1] Fan Li;Ye Ting;Chen Jing(Cancer Center,Union Hospital,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022

出　　处：《中华医学杂志》2022年第31期2405-2410,共6页National Medical Journal of China

摘　　要：晚期软组织肉瘤患者的系统性治疗以化疗为主,免疫治疗仅对部分亚型有效,以培唑帕尼和安罗替尼为代表的抗血管生成小分子酪氨酸激酶抑制剂作为靶向治疗的主要药物,已被国内外指南明确推荐为非特指型软组织肉瘤的二线治疗。近年来这类药物除了用于晚期二线单药治疗,其在二线联合治疗、维持治疗、一线治疗和新辅助治疗等方面也陆续开展了相关研究。本文现就抗血管生成小分子酪氨酸激酶抑制剂在软组织肉瘤中的应用现状及展望做简要述评。Chemotherapy is the main systemic treatment for patients with advanced soft tissue sarcoma,and immunotherapy is only effective for some special subtypes.Anti-angiogenic small molecule tyrosine kinase inhibitors represented by pazopanib and anlotinib are the main drugs of targeted therapy.They have been clearly recommended as the second-line treatment of non-specific soft tissue sarcoma in guidelines.In recent years,in addition to second-line monotherapy in patients with advanced sarcoma,some studies have been carried out in second-line combination therapy,maintenance therapy,first-line therapy and neoadjuvant therapy.This article briefly reviews the application status and prospect of anti-angiogenic small molecule tyrosine kinase inhibitors in advanced soft tissue sarcoma.

关 键 词：软组织肿瘤 软组织肉瘤 小分子酪氨酸激酶抑制剂 抗血管生成 靶向治疗 联合治疗 

分 类 号：R738.6[医药卫生—肿瘤]